Tuberculosis Trial, Recruiting (NCT06585358)

Tuberculosis Trial, Recruiting NCT06585358 Sponsor: Karolinska Institutet Condition: Tuberculosis

Printed from Voxsanity (voxsanity.com.au) — NCT06585358 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Tuberculosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Adults aged 18 or older who have been diagnosed with tuberculosis (TB) in the lungs, confirmed through a laboratory culture or a specific type of lab test (PCR)
People whose TB treatment includes the antibiotic rifampin, whether that treatment is already underway or being planned
People who are willing and able to provide written consent to participate

Who may not be able to join:

People who have already been taking rifampin for their TB for more than 8 weeks before joining the trial
People who are receiving rifampin through an intravenous drip (into a vein), including those being treated in an intensive care unit (ICU) or those with TB affecting the brain
People who have already had a rifampin drug level test (a blood test to measure how much of the drug is in the body) performed more than 24 hours before joining the trial
People who have TB only in parts of the body other than the lungs, with no lung TB present

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Lina Davies Forsman, MD, PhD, Karolinska Institutet

Phone: 08-12370000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06585358

Sponsor: Karolinska Institutet

Phase: Not Applicable

Status: Recruiting

Condition: Tuberculosis

Trial contact: 08-12370000

More information: https://clinicaltrials.gov/study/NCT06585358

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Adults aged 18 or older who have been diagnosed with tuberculosis (TB) in the lungs, confirmed through a laboratory culture or a specific type of lab test (PCR)
People whose TB treatment includes the antibiotic rifampin, whether that treatment is already underway or being planned
People who are willing and able to provide written consent to participate

Who may not be able to join:

People who have already been taking rifampin for their TB for more than 8 weeks before joining the trial
People who are receiving rifampin through an intravenous drip (into a vein), including those being treated in an intensive care unit (ICU) or those with TB affecting the brain
People who have already had a rifampin drug level test (a blood test to measure how much of the drug is in the body) performed more than 24 hours before joining the trial
People who have TB only in parts of the body other than the lungs, with no lung TB present

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Karolinska Institutet

Registry

ClinicalTrials.gov

Start date

1 November 2025

Est. completion

1 October 2027

Where this trial is recruiting

🇸🇪 Sweden

Primary endpoints

Proportion of predicted dose

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov